Foghorn Therapeutics has been granted a patent for compounds designed to treat BAF complex-related disorders. The compounds have a specific structure outlined in the claim. GlobalData’s report on Foghorn Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Foghorn Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Foghorn Therapeutics's grant share as of February 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
Compounds for treating baf complex-related disorders
A recently granted patent (Publication Number: US11851445B2) discloses a compound with a specific structure, as outlined in the claims. The compound is utilized in the creation of pharmaceutical compositions, as detailed in subsequent claims. These pharmaceutical compositions contain the compound with the specified structure, indicating its importance in the development of potential medical treatments.
The patent claims highlight the significance of the compound's structure in the pharmaceutical field, emphasizing its potential therapeutic value. By specifying the structure of the compound and its incorporation into pharmaceutical compositions, the patent provides a foundation for further research and development in the healthcare industry. This patent serves as a valuable asset for companies and researchers looking to explore the potential applications of this compound in various medical treatments.
To know more about GlobalData’s detailed insights on Foghorn Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.